WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will unveil Quell™, the Company’s wearable pain relief device at the International Consumer Electronics Show (CES) in Las Vegas in January 2015.
Quell™ utilizes NeuroMetrix’s proprietary non-invasive neurostimulation technology to provide relief from chronic pain, particularly neuropathic pain such as due to diabetes and lower back problems. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy. The Company expects Quell™ to be available for purchase by consumers in the second quarter of 2015.
“We are excited to be on the cusp of entering the $4B US over-the-counter pain relief market. We believe that as advanced wearable therapeutic technology, Quell™ represents a new pain relief category that will be attractive to consumers looking for non-pharmacological pain control options,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix.
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit http://www.NeuroMetrix.com.